Dry powder formulation of azithromycin for COVID-19 therapeutics
Azithromycin is an antibiotic proposed as a treatment for the coronavirus disease 2019 (COVID-19) due to its immunomodulatory activity. The aim of this study is to develop dry powder formulations of azithromycin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocomposite microparticles for pulmonary delivery to improve the low bioavailability of azithromycin. Double emulsion method was used to produce nanoparticles, which were then spray dried to form nanocomposite microparticles. Encapsulation efficiency and drug loading were analysed, and formulations were characterised by particle size, zeta potential, morphology, crystallinity and in-vitro aerosol dispersion performance. The addition of chitosan changed the neutrally-charged azithromycin only formulation to positively-charged nanoparticles. However, the addition of chitosan also increased the particle size of the formulations. It was observed in the NGI® data that there was an improvement in dispersibility of the chitosan-related formulations. It was demonstrated in this study that all dry powder formulations were able to deliver azithromycin to the deep lung regions, which suggested the potential of using azithromycin via pulmonary drug delivery as an effective method to treat COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 40(2023), 4 vom: 30. Juni, Seite 217-232 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chan, Stefanie Ho Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2023.2175924 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352619384 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352619384 | ||
| 003 | DE-627 | ||
| 005 | 20231226054136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2023.2175924 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352619384 | ||
| 035 | |a (NLM)36752024 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chan, Stefanie Ho Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dry powder formulation of azithromycin for COVID-19 therapeutics |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Azithromycin is an antibiotic proposed as a treatment for the coronavirus disease 2019 (COVID-19) due to its immunomodulatory activity. The aim of this study is to develop dry powder formulations of azithromycin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocomposite microparticles for pulmonary delivery to improve the low bioavailability of azithromycin. Double emulsion method was used to produce nanoparticles, which were then spray dried to form nanocomposite microparticles. Encapsulation efficiency and drug loading were analysed, and formulations were characterised by particle size, zeta potential, morphology, crystallinity and in-vitro aerosol dispersion performance. The addition of chitosan changed the neutrally-charged azithromycin only formulation to positively-charged nanoparticles. However, the addition of chitosan also increased the particle size of the formulations. It was observed in the NGI® data that there was an improvement in dispersibility of the chitosan-related formulations. It was demonstrated in this study that all dry powder formulations were able to deliver azithromycin to the deep lung regions, which suggested the potential of using azithromycin via pulmonary drug delivery as an effective method to treat COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibiotic | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a chitosan | |
| 650 | 4 | |a dry powder formulations | |
| 650 | 4 | |a dry powder inhaler | |
| 650 | 4 | |a nanocomposite microparticles | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a poly(lactic-co-glycolic acid) (PLGA) | |
| 650 | 4 | |a pulmonary drug delivery | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 700 | 1 | |a Sheikh, Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Zariwala, Mohammed Gulrez |e verfasserin |4 aut | |
| 700 | 1 | |a Somavarapu, Satyanarayana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 40(2023), 4 vom: 30. Juni, Seite 217-232 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:4 |g day:30 |g month:06 |g pages:217-232 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2023.2175924 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 4 |b 30 |c 06 |h 217-232 | ||